Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma
- PMID: 32165253
- DOI: 10.1016/j.jhep.2020.03.005
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma
Erratum in
-
Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].J Hepatol. 2020 Nov;73(5):1295-1296. doi: 10.1016/j.jhep.2020.08.029. Epub 2020 Sep 10. J Hepatol. 2020. PMID: 32921509 No abstract available.
Abstract
Background & aims: Few studies have been conducted to compare the efficacies of stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA). Thus, in this multinational study, we compared the effectiveness of SBRT and RFA in patients with unresectable HCC.
Methods: The retrospective study cohort included 2,064 patients treated in 7 hospitals: 1,568 and 496 in the RFA and SBRT groups, respectively. More than half of the patients (56.5%) developed recurrent tumors, mainly after transarterial chemoembolization (44.8%). Propensity score matching was performed to adjust for clinical factors (n = 313 in each group).
Results: At baseline, the SBRT group had unfavorable clinical features compared to the RFA group, including BCLC stage (B-C 65% vs. 16%), tumor size (median 3.0 cm vs. 1.9 cm), and frequent history of liver-directed treatment (81% vs. 49%, all p <0.001). With a median follow-up of 27.7 months, the 3-year cumulative local recurrence rates in the SBRT and RFA groups were 21.2% and 27.9%, respectively (p <0.001). After adjusting for clinical factors, SBRT was related to a significantly lower risk of local recurrence than RFA in both the entire (hazard ratio [HR] 0.45, p <0.001) and matched (HR 0.36, p <0.001) cohorts. In subgroup analysis, SBRT was associated with superior local control in small tumors (≤3 cm) irrespective of location, large tumors located in the subphrenic region, and those that progressed after transarterial chemoembolization. Acute grade ≥3 toxicities occurred in 1.6% and 2.6% of the SBRT and RFA patients, respectively (p = 0.268).
Conclusions: SBRT could be an effective alternative to RFA for unresectable HCC, particularly for larger tumors (>3 cm) in a subphrenic location and tumors that have progressed after transarterial chemoembolization.
Lay summary: It is currently not known what the best treatment option is for patients with unresectable hepatocellular carcinoma. Here, we show that stereotactic body radiation therapy provides better local control than radiofrequency ablation, with comparable toxicities. Stereotactic body radiation therapy appears to be an effective alternative to radiofrequency ablation that should be considered when there is a higher risk of local recurrence or toxicity after radiofrequency ablation.
Keywords: Hepatocellular carcinoma; Local control; Prognosis; Propensity score matching; Radiofrequency ablation; Stereotactic body radiation therapy.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role.J Hepatol. 2020 Jul;73(1):15-16. doi: 10.1016/j.jhep.2020.04.019. Epub 2020 May 6. J Hepatol. 2020. PMID: 32386956 No abstract available.
-
Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?J Hepatol. 2020 Aug;73(2):467-468. doi: 10.1016/j.jhep.2020.03.016. Epub 2020 May 11. J Hepatol. 2020. PMID: 32409208 No abstract available.
-
Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data.J Hepatol. 2020 Sep;73(3):727-728. doi: 10.1016/j.jhep.2020.04.017. Epub 2020 May 15. J Hepatol. 2020. PMID: 32423631 No abstract available.
-
Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?".J Hepatol. 2020 Aug;73(2):468-469. doi: 10.1016/j.jhep.2020.04.016. Epub 2020 May 25. J Hepatol. 2020. PMID: 32467075 No abstract available.
-
Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".J Hepatol. 2020 Oct;73(4):973-974. doi: 10.1016/j.jhep.2020.05.031. Epub 2020 Jul 6. J Hepatol. 2020. PMID: 32646619 No abstract available.
-
Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers.J Hepatol. 2020 Oct;73(4):972-973. doi: 10.1016/j.jhep.2020.05.018. Epub 2020 Aug 6. J Hepatol. 2020. PMID: 32771324 No abstract available.
Similar articles
-
Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.Radiother Oncol. 2019 Feb;131:81-87. doi: 10.1016/j.radonc.2018.12.013. Epub 2018 Dec 31. Radiother Oncol. 2019. PMID: 30773192
-
Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.BMC Cancer. 2021 Oct 30;21(1):1169. doi: 10.1186/s12885-021-08897-z. BMC Cancer. 2021. PMID: 34717577 Free PMC article.
-
Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma.Eur J Gastroenterol Hepatol. 2022 Nov 1;34(11):1187-1194. doi: 10.1097/MEG.0000000000002442. Epub 2022 Sep 10. Eur J Gastroenterol Hepatol. 2022. PMID: 36170689
-
An overview of stereotactic body radiation therapy for hepatocellular carcinoma.Expert Rev Gastroenterol Hepatol. 2020 Apr;14(4):271-279. doi: 10.1080/17474124.2020.1744434. Expert Rev Gastroenterol Hepatol. 2020. PMID: 32223683 Review.
-
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.Digestion. 2017;96(1):1-4. doi: 10.1159/000464282. Epub 2017 Jun 13. Digestion. 2017. PMID: 28605745 Free PMC article. Review.
Cited by
-
Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm.JHEP Rep. 2024 Jun 25;6(10):101151. doi: 10.1016/j.jhepr.2024.101151. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39308987 Free PMC article.
-
Expanding Indications for Liver Transplantation in the Treatment of Hepatocellular Carcinoma.Curr Oncol. 2024 Aug 20;31(8):4753-4761. doi: 10.3390/curroncol31080355. Curr Oncol. 2024. PMID: 39195338 Free PMC article. Review.
-
Temporal trends and long-term outcomes of radiofrequency ablation for hepatocellular carcinoma within the Milan criteria.Sci Rep. 2024 Aug 27;14(1):19815. doi: 10.1038/s41598-024-70494-4. Sci Rep. 2024. PMID: 39191840 Free PMC article.
-
Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study.Front Surg. 2024 Aug 7;11:1387246. doi: 10.3389/fsurg.2024.1387246. eCollection 2024. Front Surg. 2024. PMID: 39170098 Free PMC article.
-
The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences.J Natl Cancer Cent. 2022 Jun 12;2(3):171-182. doi: 10.1016/j.jncc.2022.05.002. eCollection 2022 Sep. J Natl Cancer Cent. 2022. PMID: 39036452 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical